In ICI therapy, some articles report that HLH incidence is more frequent with the use of CTLA-4 inhibitors in comparison to PD(L)-1 inhibitors for mechanisms that remain unknown [2]. Here, CTLA4 is linked to hemophagocytic syndrome.